NASDAQ:LMAT - LeMaitre Vascular Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $36.69 +0.33 (+0.91 %) (As of 07/17/2018 04:00 PM ET)Previous Close$36.36Today's Range$36.36 - $36.8252-Week Range$27.90 - $41.28Volume50,600 shsAverage Volume151,049 shsMarket Capitalization$706.05 millionP/E Ratio42.66Dividend Yield0.77%Beta0.57 Company ProfileFinancialsAnalyst RatingsDividend HistoryEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature. It also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; powered phlebectomy devices to remove varicose veins; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, the company offers remote endarterectomy devices to remove plaque from arteries in the leg; valvulotomes that cuts valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, it provides vascular patches, which are used for closure of vessels after surgical intervention, as well as endarterectomy and other vascular reconstruction; vessel closure systems to attach vessels to one another with titanium clips instead of sutures; and Reddick cholangiogram catheters to inject dye into the cystic duct during laparoscopic cholecystectomy, as well as laparoscopic accessory for use in laparoscopic gall bladder removal. LeMaitre Vascular, Inc. markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was founded in 1983 and is headquartered in Burlington, Massachusetts. Receive LMAT News and Ratings via Email Sign-up to receive the latest news and ratings for LMAT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical SymbolNASDAQ:LMAT CUSIPN/A Webwww.lemaitre.com Phone781-221-2266 Debt Debt-to-Equity RatioN/A Current Ratio6.65 Quick Ratio4.92 Price-To-Earnings Trailing P/E Ratio42.66 Forward P/E Ratio33.66 P/E Growth2.24 Sales & Book Value Annual Sales$100.87 million Price / Sales7.02 Cash Flow$1.1058 per share Price / Cash33.18 Book Value$5.70 per share Price / Book6.44 Profitability EPS (Most Recent Fiscal Year)$0.86 Net Income$17.17 million Net Margins17.34% Return on Equity16.66% Return on Assets14.57% Miscellaneous Employees423 Outstanding Shares19,310,000Market Cap$706.05 LeMaitre Vascular (NASDAQ:LMAT) Frequently Asked Questions What is LeMaitre Vascular's stock symbol? LeMaitre Vascular trades on the NASDAQ under the ticker symbol "LMAT." How often does LeMaitre Vascular pay dividends? What is the dividend yield for LeMaitre Vascular? LeMaitre Vascular declared a quarterly dividend on Monday, April 23rd. Investors of record on Tuesday, May 22nd will be paid a dividend of $0.07 per share on Thursday, June 7th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.76%. The ex-dividend date of this dividend is Monday, May 21st. View LeMaitre Vascular's Dividend History. How will LeMaitre Vascular's stock buyback program work? LeMaitre Vascular announced that its Board of Directors has initiated a share repurchase plan on Friday, July 28th 2017, which allows the company to buyback $7,500,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to reacquire up to 1.4% of its shares through open market purchases. Shares buyback plans are usually a sign that the company's board of directors believes its shares are undervalued. How were LeMaitre Vascular's earnings last quarter? LeMaitre Vascular Inc (NASDAQ:LMAT) issued its earnings results on Wednesday, April, 25th. The medical instruments supplier reported $0.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.21 by $0.02. The medical instruments supplier had revenue of $25.99 million for the quarter, compared to the consensus estimate of $26.42 million. LeMaitre Vascular had a return on equity of 16.66% and a net margin of 17.34%. LeMaitre Vascular's revenue for the quarter was up 7.8% compared to the same quarter last year. During the same period last year, the business posted $0.16 EPS. View LeMaitre Vascular's Earnings History. What guidance has LeMaitre Vascular issued on next quarter's earnings? LeMaitre Vascular updated its FY18 earnings guidance on Wednesday, April, 25th. The company provided earnings per share guidance of $1.05-1.13 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.98. The company issued revenue guidance of $106-109 million, compared to the consensus revenue estimate of $111.05 million.LeMaitre Vascular also updated its Q2 guidance to $0.41-0.43 EPS. What price target have analysts set for LMAT? 6 Wall Street analysts have issued 1-year target prices for LeMaitre Vascular's shares. Their predictions range from $34.00 to $45.00. On average, they expect LeMaitre Vascular's share price to reach $37.6667 in the next twelve months. This suggests a possible upside of 2.7% from the stock's current price. View Analyst Ratings for LeMaitre Vascular. What is the consensus analysts' recommendation for LeMaitre Vascular? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LeMaitre Vascular in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Who are some of LeMaitre Vascular's key competitors? Some companies that are related to LeMaitre Vascular include Merit Medical Systems (MMSI), NuVasive (NUVA), Irhythm Technologies (IRTC), Nevro (NVRO), Mazor Robotics (MZOR), Glaukos (GKOS), Luminex (LMNX), Tandem Diabetes Care (TNDM), Cardiovascular Systems (CSII), Atrion (ATRI), Orthofix International (OFIX), Cryolife (CRY), OraSure Technologies (OSUR), Intersect ENT (XENT) and AtriCure (ATRC). Who are LeMaitre Vascular's key executives? LeMaitre Vascular's management team includes the folowing people: Mr. George W. LeMaitre, Chairman & CEO (Age 53)Mr. David B. Roberts, Pres & Director (Age 54)Mr. Joseph P. Pellegrino Jr., CFO, Treasurer, Sec. & Director (Age 53)Mr. Trent G. Kamke, Sr. VP of Operations (Age 47)Dr. George D. LeMaitre, Founder and Chairman of Scientific Advisory Board (Age 84) Has LeMaitre Vascular been receiving favorable news coverage? Media stories about LMAT stock have been trending somewhat positive this week, Accern reports. The research firm identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. LeMaitre Vascular earned a coverage optimism score of 0.08 on Accern's scale. They also assigned news coverage about the medical instruments supplier an impact score of 45.30 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future. Who are LeMaitre Vascular's major shareholders? LeMaitre Vascular's stock is owned by a number of of institutional and retail investors. Top institutional investors include Summit Creek Advisors LLC (1.11%) and Concorde Asset Management LLC (0.11%). Company insiders that own LeMaitre Vascular stock include Cornelia W Lemaitre, David B Roberts, George W Lemaitre, Lawrence J Jasinski, Michael T Wijas, Peter R Gebauer and Trent G Kamke. View Institutional Ownership Trends for LeMaitre Vascular. Which major investors are buying LeMaitre Vascular stock? LMAT stock was purchased by a variety of institutional investors in the last quarter, including Summit Creek Advisors LLC and Concorde Asset Management LLC. View Insider Buying and Selling for LeMaitre Vascular. How do I buy shares of LeMaitre Vascular? Shares of LMAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is LeMaitre Vascular's stock price today? One share of LMAT stock can currently be purchased for approximately $36.69. How big of a company is LeMaitre Vascular? LeMaitre Vascular has a market capitalization of $706.05 million and generates $100.87 million in revenue each year. The medical instruments supplier earns $17.17 million in net income (profit) each year or $0.86 on an earnings per share basis. LeMaitre Vascular employs 423 workers across the globe. How can I contact LeMaitre Vascular? LeMaitre Vascular's mailing address is 63 SECOND AVENUE, BURLINGTON MA, 01803. The medical instruments supplier can be reached via phone at 781-221-2266. MarketBeat Community Rating for LeMaitre Vascular (NASDAQ LMAT)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 299 (Vote Outperform)Underperform Votes: 197 (Vote Underperform)Total Votes: 496MarketBeat's community ratings are surveys of what our community members think about LeMaitre Vascular and other stocks. Vote "Outperform" if you believe LMAT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LMAT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/17/2018 by MarketBeat.com StaffFeatured Article: What does RSI mean?